Precigen Beheer
Beheer criteriumcontroles 4/4
De CEO Precigen is Helen Sabzevari, benoemd in Jan2020, heeft een ambtstermijn van 6.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.35M, bestaande uit 18.7% salaris en 81.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.05% van de aandelen van het bedrijf, ter waarde $ 27.14M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.6 jaar en 12.3 jaar.
Belangrijke informatie
Helen Sabzevari
Algemeen directeur
US$5.4m
Totale compensatie
| Percentage CEO-salaris | 18.68% |
| Dienstverband CEO | 6.6yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | 6.6yrs |
| Gemiddelde ambtstermijn bestuur | 12.3yrs |
Recente managementupdates
Recent updates
Rising Reimbursement And Trial Risks Will Test Long-Term Immunotherapy Potential
Catalysts About Precigen Precigen is a biotechnology company focused on immunotherapies, including PAPZIMEOS for adults with recurrent respiratory papillomatosis and pipeline programs such as PRGN-2009 for HPV related cancers. What are the underlying business or industry changes driving this perspective?Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement
Summary Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis (RRP). PGEN achieved profitability in Q2 2026 with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity. Potential European approval of PAPZIMEOS and expansion of the AdenoVerse Immunotherapy platform, notably PRGN-2009, could unlock significant new market opportunities. Key catalysts include EMA review of PRGN-2012 and PRGN-2009 data updates by the end of 2026, with break-even cash flow targeted by year-end. Read the full article on Seeking Alpha
AdenoVerse Platform And First-Line RRP Therapy Will Shape Powerful Long-Term Earnings Potential
Catalysts About Precigen Precigen is a biotechnology company focused on developing and commercializing immunotherapies, including PAPZIMEOS for adults with recurrent respiratory papillomatosis and pipeline programs such as PRGN-2009 that use its AdenoVerse platform. What are the underlying business or industry changes driving this perspective?
PGEN: Orphan Exclusivity And Early RRP Uptake Will Drive Future Upside
Analysts have lifted the Precigen fair value estimate from $12.45 to $14.50, citing higher Street price targets attributed to Papzimeos sales that have exceeded guidance and recent FDA orphan-drug exclusivity for the therapy. Analyst Commentary Recent Street research on Precigen centers on Papzimeos launch execution and the impact of FDA orphan-drug exclusivity on the company’s revenue potential and valuation framework.PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside
Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking AlphaPrecigen: Successful Proof Of Platform, But Cash Worries Remain
Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$337m |
| Mar 31 2026 | n/a | n/a | -US$383m |
| Dec 31 2025 | US$5m | US$1m | -US$430m |
| Sep 30 2025 | n/a | n/a | -US$426m |
| Jun 30 2025 | n/a | n/a | -US$124m |
| Mar 31 2025 | n/a | n/a | -US$157m |
| Dec 31 2024 | US$5m | US$1m | -US$126m |
| Sep 30 2024 | n/a | n/a | -US$140m |
| Jun 30 2024 | n/a | n/a | -US$135m |
| Mar 31 2024 | n/a | n/a | -US$97m |
| Dec 31 2023 | US$4m | US$1m | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$79m |
| Dec 31 2022 | US$3m | US$1m | -US$80m |
| Sep 30 2022 | n/a | n/a | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$3m | US$1m | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$124m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | US$20m | US$1m | -US$104m |
| Sep 30 2020 | n/a | n/a | -US$100m |
| Jun 30 2020 | n/a | n/a | -US$122m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$1m | US$500k | -US$169m |
Compensatie versus markt: De totale vergoeding ($USD 5.35M ) Helen } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.92M ).
Compensatie versus inkomsten: De vergoeding van Helen is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Helen Sabzevari (64 yo)
Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 18.5yrs | US$600.00k | 3.74% $ 96.5m | |
| President | 6.6yrs | US$5.35m | 1.05% $ 27.1m | |
| Chief Financial Officer | 4.8yrs | US$1.49m | 0.071% $ 1.8m | |
| Chief Operating Officer | 6.5yrs | US$1.56m | 0.13% $ 3.3m | |
| Chief Legal Officer & Corporate Secretary | 15.6yrs | US$1.43m | 0.21% $ 5.4m | |
| Chief Commercial Officer | 2.1yrs | US$1.23m | 0.039% $ 1.0m | |
| VP & Head of Investor Relations | 8.6yrs | geen gegevens | geen gegevens | |
| Senior VP & Head of Research | no data | geen gegevens | geen gegevens | |
| Senior VP & Head of CMC | no data | geen gegevens | geen gegevens | |
| Senior VP & Head of Clinical Operations and Regulatory Affairs | 3.2yrs | geen gegevens | geen gegevens | |
| Chief Executive Officer of MBP Titan LLC | 7.6yrs | geen gegevens | geen gegevens |
Ervaren management: Het managementteam van PGEN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 18.5yrs | US$600.00k | 3.74% $ 96.5m | |
| President | 6.2yrs | US$5.35m | 1.05% $ 27.1m | |
| Independent Director | 14.8yrs | US$319.00k | 0.056% $ 1.5m | |
| Independent Director | 10.2yrs | US$313.00k | 0.35% $ 9.0m | |
| Independent Director | 18.5yrs | US$312.50k | 0.22% $ 5.6m | |
| Lead Independent Director | 12.3yrs | US$312.50k | 0.19% $ 4.9m | |
| Independent Director | 18.5yrs | US$300.00k | 0.34% $ 8.8m | |
| Independent Director | 2.1yrs | US$306.50k | 0.085% $ 2.2m | |
| Independent Director | 9.3yrs | US$313.00k | 0.19% $ 4.8m |
Ervaren bestuur: De raad van bestuur van PGEN zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.3 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/24 22:17 |
| Aandelenkoers aan het einde van de dag | 2026/08/24 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Precigen, Inc. wordt gevolgd door 10 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |